This probably caused the failure of Randomized Clinical Trial for KRAS-mutant non-small cell lung cancer (NSCLC) without significant improvement in progression-free survival (Jänne et al., 2017). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.